Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Renalytix ( (GB:RENX) ) just unveiled an announcement.
Renalytix has published its Annual Report for the year ending June 2025 and announced the Notice of its 2025 Annual General Meeting. The company continues to expand the deployment of its kidneyintelX.dkd test, which has shown significant improvements in diagnosis and treatment rates for kidney disease. The test is now fully reimbursed by Medicare and recommended in international clinical guidelines, reinforcing Renalytix’s position in the healthcare industry.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Underperform.
Renalytix’s overall stock score is low due to severe financial challenges, including declining revenues, high operating losses, and solvency issues. Despite positive corporate events suggesting strategic interest and growth potential, the technical analysis and valuation remain weak, impacting the stock’s appeal.
To see Spark’s full report on GB:RENX stock, click here.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to improve patient outcomes. The company has developed kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test for early-stage risk assessment in chronic kidney disease, which is commercially available in the United States.
Average Trading Volume: 4,992,571
Technical Sentiment Signal: Strong Sell
Current Market Cap: £32.25M
Find detailed analytics on RENX stock on TipRanks’ Stock Analysis page.